Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

TSH-Receptor-Antibodies (TSHR-AB) Help to Predict Severity and Outcome of Graves’ Ophthalmopathy (GO)

Eckstein A.1, Plicht M.1, Morgenthaler N.4, Steuhl K. P.1, Renzing-Köhler K.3, Quadbeck B.2, Mann K.2, Esser J.1
1Department of Ophthalmology, 2Department of Medicine, Division of Endocrinology, 3Institute for Medical Informatics, Biometry and Epidemiology, University Essen; 4BRAHMS AG, Research, Biotechnology Centre Hennigsdorf/Berlin, Germany

Purpose: There are no useful biomarkers known to assess the prognosis of the GO, which makes the management of GO very difficult. The association between TSHR-AB and GO is still a mater of debate. The aim of this study was to evaluate the value of TSHR-AB for the prognosis of GO by the retrospective analysis of prospectively collected follow up data of GO patients.
Method: 67 patients with GO have been followed for two years. Patients were divided into two groups (according to the course of the clinical activity score (CAS) and the severity the disease: modified NOSPECS score). Severe GO (n=30): CAS >8, NOSPECS >7 at first visit, CAS 4-7, NOSPECS 3-6 at first visit with increasing or unchanging values, CAS <4, NOSPECS <3 at first visit and increasing values. Mild to moderate GO(n=37): CAS 4-7, NOSPECS 3-6 at first visit with decreasing values or CAS <4, NOSPECS <3 at first visit with maintaining or decreasing values. TSHR-AB (TBII, TRAKhuman, BRAHMS, Germany) were measured w


Zurück | Back